Molecular Future

Cheerleading commentary and raw opinion on bio-business and molecular medicine.

Pages

Home

Thursday, September 19, 2013

Food for thought: Curing Cancer Isn't Really Worth All The Trouble

Worth a quick read......

Per GOOGLE: Curing Cancer Isn't Really Worth All The Trouble
http://www.businessinsider.com/google-curing-cancer-isnt-really-worth-all-the-trouble-2013-9

Posted by TimmyG No comments:

Email This BlogThis!Share to X Share to Facebook Share to Pinterest

Labels: cancer, GOOG, strategy

Newer Posts Older Posts Home

Subscribe to: Posts (Atom)

What is "Molecular Future?"

Molecular Future is the optimistic idea that:

-'Molecular medicine' tech such as DNA sequencing, targeted therapeutics, and pharmacogenomics will power a great leap forward in health care over the next decade.

-The cost to care ratio will fall dramatically because of 'molecular medicine.'

-Technical advances are accelerating.

-There has never been a better time to be in the business of advancing human health.

I also believe that the Molecular Future means many new challenges; business strategies need to evolve, Big Pharma needs to adopt new models, regulators need to adopt new attitudes, and new ethical questions need answers.

Subscribe!

Posts

Posts

All Comments

All Comments

Popular Posts

Intrexon In-trouble?
Interesting pharma M&A stat….
Exelixis: all-in on cabo
Celldex's triple-negative breast cancer progress
Genomes-R-Us: Is BGI now Complete?
Dako acquired by Agilent
Called it (Affymetrix-eBioscience)!
Tim Gallagher shared an article with you from Pocket
What a biotech hedge fund thinks of coming regulatory decisions.
Transgenic (& biosimilar!) FDA approval!

Biotech blogs

Life Sci VC

Atlas XIV And Reflections On The VC Math Problem
2 weeks ago
Omics! Omics!

Benchtop HiFi: PacBio Unveils Vega
1 month ago
Genomes Unzipped

Best Genealogy Software
4 years ago
The Daily Scan from GenomeWeb

NIH Boost Proposed
6 years ago
TheStreet Search RSS Feed: Adam Feuerstein

Gilead (GILD) Stock Down as Merck Wins Patents Dispute
8 years ago
The IN VIVO Blog

IN VIVO Blog Is No More.
9 years ago
The Medicine Show

30 Under 30: The Entrepreneurs Making Healthcare Digital
9 years ago
Pharma Strategy Blog

Developing a predictive biomarker for PARP inhibition
10 years ago
The Big Red Biotech Blog
In the Pipeline

Try these sites too......

Matt Ridley's Rational Optimist blog. Science & society, with a bias towards genetics
David E. Duncan - one of today's best and most accessible longform science writers
Forbes' Matthew Herper - one of the best and most accessible short form science writers
Fierce Biotech - great source for daily news
Genomics Law Report
MassGenomics
MIT's Technology Review (biomed section)

Resources

Baker Bros portfolio
BioPharmCatalyst
FDA Tracker
Seeking Alpha

About Me

TimmyG: Marketing, development, and strategy guy; RX, DX, PGX, discovery tools & services veteran; early-stage biotech entrepreneur. Find me on LinkedIn

View my complete profile

Clustr Map

Blog Archive

► 2015 (1)
- ► February (1)

► 2014 (4)
- ► November (2)
- ► March (1)
- ► February (1)

▼ 2013 (10)
- ▼ September (1)
  - Food for thought: Curing Cancer Isn't Really Worth...
- ► June (1)
- ► May (1)
- ► April (4)
- ► January (3)

► 2012 (84)
- ► October (1)
- ► September (4)
- ► August (3)
- ► July (1)
- ► June (2)
- ► May (20)
- ► April (23)
- ► March (15)
- ► February (14)
- ► January (1)

► 2011 (9)
- ► December (1)
- ► November (1)
- ► April (1)
- ► March (4)
- ► February (1)
- ► January (1)

Labels

$1000 genome 1000 Genome Project 23andme 454 A Abcam ABT acquisition target Actavis Adam Feuerstein Aeterna AFFX Afinitor Agilent Alex Denner ALK all-in ALS AMG 102 AMGN AMLN Amylin AMZN analysis antibody antibody linker antigen approval Argonex arrogance ASCO AUXL Avastin AZN backseat driving bad CEO bad data Baker Bros baseball Bayer BCR-ABL behavior BGI big biotech Big Data big pharma Big Pharma VC BIIB bio-bucks bio-dollars BioCentury Biocon biologics biomarker biosimilars biotech biz over IP Bjorn Lomborg BMS brain freeze breast Brennan Bruce Booth bubble Burrill business business models buyer's market Cabo Cabozantinib Calibr California Calpresa cancer cancer clinical trials capital Carfilzomib Carl Icahn Carticel cause of disease CDX-011 Celera CELG Celldex CEPH Cerezyme CF CGOM China cholesterol CIRM CLDX clinical diagnostics cloud computing CML colon cancer compound rescue consumables CRC CRO CVM Daiichi Dako Danaher demand derisked biotech acqusisition for pharma Desmond-Hellman DGX dividend DIY DNA DNA sequencing DNDN drug approvals drug development drug discovery drug discovery paradigm Druker DX early stage eBioscience economic development EGFR Ego Elelyso environment epigenetics Epitomics equipment equity ER Erbitux ethics Europe Everolimus EXEL F508del FDA FDA/NCI idea Felix Salmon FierceBiotech finance financing Fluidigm Forbes mag Foundation Medicine FoundationOne Francis Collins freedom FRX funding cliff Gaucher's disease GE Gen-Probe Genentech Generics genes genetics genomics GENZ geography GERN GHDX GHTC GILD GIST Gleevec GNOM GOOG government vs private sector research GPCR GPNMB GPRO greater fool Greg Lucier growth strategy GSK GXDX HALO HBV health care debate hedge fund Hep C HER-2 Herceptin HGF HGSI HIG Ventures hit rates HIV Hologic HOLX HPV HTS hype idea ILMN IMCL immune response immunotherapy in trouble Incyte India industry infectious disease inflammation Intrexon Introduction investing investment InVitae Ion Torrent IP Group IP2IPO IPO.L IPR Iressa Jeff Kindler Jeff Leiden JNJ Jonathan Rothberg KAI Pharma Kalydeco Kauffman Foundation Keryx kinase Kinsella layoffs Leslie Frazier Levinson libertarian LIFE LifeSciVC Lilly LLY Lucentis Luddites lung mainstream MandA map Marginal Revolution Matt Ridley MDX MEDI Merck KgA Mergers and Acquisitions MET molecular diagnostics MolecularMD MRK mTor multiple myeloma mutation MYGN Myriad Nature Navigenics NCATS NEJM new CEO new tech new ventures Nexavar NGS NIH NOT MF notgonnahappen NSCLC NVS OCF+ ONXX Oops Origene OSIP OT Oxford Oxford Nanopore partnership math partnerships patent cliff patents PCR personal experience personal genomics personalized medicine PFE Pfizer PGX Pharma models Phase 2B phenotype vs. target PI3K pipeline Plexxikon policy politics post-hype PPH PR pre-natal privacy private prostate Protalix protein arrays ProVenge PSCK9 public pure-play QGEN Quake quick hits raider Rand Paul RandD productivity Randy Scott rant Rational Optimist Read this reagents reality reform REGN Regorafenib regulation regulatory capture repurposing research RET RHHBY Rilotumumab risk RJ Kirk Roche rock star ROI Sarbox secondary markets Seeking Alpha sequencing sequencing hardware SeqWright services SGEN signs of life SNY society SP500 Sprycel start-up stats stem cell stem cells stock performance stocks strategy Sutent synthetic biology T-DM1 targeted RX Tasigna TBIO TECH technologies Telapivir Termeer TG owns Thermo FIsher Third Rock Third Security TNBC tools transactions Transgenics translational medicine tumor expression Tykerb Tyler Cowen under the microscope USA valuation VC VC model Vectibix VEGFR Verinata Very cool virtual Vogelstein von Eschenbach VRTX VX-809 Warp Drive Bio Warp Speed Watson WSJ Xalkori Xcovery XNA Zaffaroni Zelboraf ZIOP

All content solely the opinion of the author.. Travel theme. Powered by Blogger.

topics of interest

companion diagnostics, personalized medicine, pharmacogenomics, PGX, RX, DX, molecular diagnostics, oncology drug development, business of biotech, genomics, arrays, multiplexing, NGS, dna sequencing, gene expression profiling, kinase, phosphorylation, phosphatase, epigenetics, chromatin, pharmaceutical, big pharma, small cap biotech, drug discovery partnership, drug development partnership, business of drug discovery tools and services, CRO, drug screening, strategy, business strategy, early stage biotech, business models, Tim Gallagher, Upstate Biotechnology, Xcovery, anti-angiogenesis, kinase inhibitors, pharma deals